317 related articles for article (PubMed ID: 26868696)
1. A Test in Context: High-Sensitivity C-Reactive Protein.
Ridker PM
J Am Coll Cardiol; 2016 Feb; 67(6):712-723. PubMed ID: 26868696
[TBL] [Abstract][Full Text] [Related]
2. Inflammation, C-reactive protein, and atherothrombosis.
Ridker PM; Silvertown JD
J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
[TBL] [Abstract][Full Text] [Related]
3. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
4. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
Everett BM; Glynn RJ; MacFadyen JG; Ridker PM
Circulation; 2010 Jan; 121(1):143-50. PubMed ID: 20026779
[TBL] [Abstract][Full Text] [Related]
6. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
Koenig W
Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
[TBL] [Abstract][Full Text] [Related]
7. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines.
Mora S; Musunuru K; Blumenthal RS
Clin Chem; 2009 Feb; 55(2):219-28. PubMed ID: 19095730
[TBL] [Abstract][Full Text] [Related]
8. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
[TBL] [Abstract][Full Text] [Related]
9. The effect of including C-reactive protein in cardiovascular risk prediction models for women.
Cook NR; Buring JE; Ridker PM
Ann Intern Med; 2006 Jul; 145(1):21-9. PubMed ID: 16818925
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
Michos ED; Blumenthal RS
J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922
[TBL] [Abstract][Full Text] [Related]
11. Circulating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial.
Akinkuolie AO; Glynn RJ; Padmanabhan L; Ridker PM; Mora S
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27413042
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.
Ridker PM
J Am Coll Cardiol; 2007 May; 49(21):2129-38. PubMed ID: 17531663
[TBL] [Abstract][Full Text] [Related]
13. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.
Ridker PM
Circulation; 2001 Apr; 103(13):1813-8. PubMed ID: 11282915
[TBL] [Abstract][Full Text] [Related]
14. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey.
Spatz ES; Canavan ME; Desai MM
Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):41-8. PubMed ID: 20031811
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein: risk factor, biomarker and/or therapeutic target?
Genest J
Can J Cardiol; 2010 Mar; 26 Suppl A():41A-44A. PubMed ID: 20386760
[TBL] [Abstract][Full Text] [Related]
16. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
Ridker PM; Wilson PW; Grundy SM
Circulation; 2004 Jun; 109(23):2818-25. PubMed ID: 15197153
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
Carter NJ
Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
[TBL] [Abstract][Full Text] [Related]
18. Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice.
Ridker PM
Am Heart Hosp J; 2004; 2(4 Suppl 1):4-9. PubMed ID: 15539969
[TBL] [Abstract][Full Text] [Related]
19. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
[TBL] [Abstract][Full Text] [Related]
20. High-sensitivity C-reactive protein: clinical importance.
Bassuk SS; Rifai N; Ridker PM
Curr Probl Cardiol; 2004 Aug; 29(8):439-93. PubMed ID: 15258556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
